REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
| Revenue (Most Recent Fiscal Year) | $83.33M |
| Net Income (Most Recent Fiscal Year) | $-227.10M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.87 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -100.62% |
| Net Margin (Trailing 12 Months) | -100.62% |
| Return on Equity (Trailing 12 Months) | -53.29% |
| Return on Assets (Trailing 12 Months) | -30.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.47 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.59 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.11 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.16M |
| Free Float | 43.74M |
| Market Capitalization | $449.94M |
| Average Volume (Last 20 Days) | 1.26M |
| Beta (Past 60 Months) | 1.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.79% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |